Skip Navigation

Philips Respironics issued a recall for some CPAP and BiLevel PAP devices and mechanical ventilators. Learn more.


COVID-19: We are vaccinating patients ages 12+. Learn more:

Vaccines & 3rd Doses | Testing | Patient Care | Visitor Guidelines | Coronavirus | Self-Checker | Email Alerts

Menu Search
The Sidney Kimmel Comprehensive Cancer Center

In This Section      

Leukemia Clinical Trials

Johns Hopkins Kimmel Cancer Center attract's many patients for our novel approaches to treatment. At the Kiimmel Cancer Center, we are conducting innovative clinical trials with new agents alone or in combination with other chemotherapy or biologic agents for all stages and all types of leukemias for adults. View our current leukemia clinical trials open at the Johns Hopkins Kimmel Cancer Center.

Top Leukemia Experts

Hopkins experts are pursuing a large number of innovative clinical trials with exciting new agents. For example, for patients with poor risk newly diagnosed with acute leukemias, Hopkins scientists are testing the investigational drug flavopiridol, a medicine that inhibits cell division, in combination with the potent anti-leukemia drugs Ara-C and mitoxantrone (FLAM).

Leukemia Research

Overall, leukemia research at the Johns Hopkins Kimmel Cancer Center is focused on several areas of study:

  • Signal Transduction
     Scientists are studying how leukemia cells transmit signals to each other to communicate and regulate cell processes. Breaking this chain of communication, most likely using several therapies, may halt the cancer’s growth and spread. Drugs under investigation include tipifarnib; FLT-3 inhibitors such as CEP-701, KW-2449, sorafenib and AC220; and bevacizumab.
  • Cell Cycle Regulation/Apoptosis
    The life cycle of a cell can be manipulated to either live longer or die sooner.  Investigators at Johns Hopkins are studying mechanisms to cut short the lifespan of leukemia cells by using drugs in combination with chemotherapy, such as flavopiridol or SNS-595.
  • DNA Repair
    In response to onslaughts of chemotherapy drugs, leukemia cells can mutate and become resistant to these therapies. Agents under investigation to block leukemia cells’ ability to repair themselves are triapine, clofarabine, ABT-888 and SCH90076.
  • Differentiation/Gene Expression
    At the Johns Hopkins Kimmel Cancer Center, scientists are studying the cellular and genetic mechanisms that lead to cancer development. Drugs that target those mechanisms, such as entinostat, SAHA, 5-azacytidine, and ATRA, may aid existing therapies and are being tested at Johns Hopkins. 
  • Immunology
    Johns Hopkins scientists are developing therapies that may help the body’s immune system fight cancer. Pioneered by basic science and clinical immunology experts at Johns Hopkins, such therapies, including vaccines, which target specific aspects of leukemia cells, are being developed for acute and chronic myelogenous leukemias.